TCGA-K4-A5RJ-01A-11R-A28M-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 17.70696452
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.600
- ADIPOGENESIS+0.530
- INTERFERON_ALPHA_RESPONSE+0.530
- ALLOGRAFT_REJECTION+0.520
- INTERFERON_GAMMA_RESPONSE+0.510
- IL6_JAK_STAT3_SIGNALING+0.480
- FATTY_ACID_METABOLISM+0.470
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.460
- E2F_TARGETS+0.440
- COMPLEMENT+0.390
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.310
- TGF_BETA_SIGNALING-0.250
- KRAS_SIGNALING_DN-0.240
- ESTROGEN_RESPONSE_LATE-0.230
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.220
- APICAL_JUNCTION-0.190
- P53_PATHWAY-0.190
- MYOGENESIS-0.170
- TNFA_SIGNALING_VIA_NFKB-0.160
- ANGIOGENESIS-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | P31FUJ_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.843 |
| 2 | TCGA-39-5011-01A-01R-1443-07 | — | cohortA1 | 0.832 |
| 3 | DRR168592 | — | — | 0.830 |
| 4 | TCGA-UF-A7JO-01A-11R-A34R-07 | — | — | 0.828 |
| 5 | TCGA-A2-A0SW-01A-11R-A084-07 | — | C | 0.820 |
| 6 | 5ffcc7c5-661f-4eed-b5e6-ed158c668321 | — | — | 0.819 |
| 7 | SRR4296112 | — | cohortA1 | 0.815 |
| 8 | SRR6013516 | — | cohortA1 | 0.808 |
| 9 | TCGA-38-4625-01A-01R-1206-07 | — | cohortA1 | 0.807 |
| 10 | TCGA-80-5611-01A-01R-1628-07 | — | cohortA4 | 0.807 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.600 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.530 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.530 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.520 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.510 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.480 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.470 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.460 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.440 | Inavolisib | — uncovered |
| COMPLEMENT | 0.390 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.360 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.340 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.320 | Inavolisib | — uncovered |
| PEROXISOME | 0.300 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.290 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.220 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.180 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |